bioanalytical-laboratories-995x60.png bioanalytical-laboratories-995x60.png

FEATURED ARTICLES

Proposed Tax Change Would Impact Clinical Research
Proposed Tax Change Would Impact Clinical Research

Pharma companies that conduct clinical research inhouse essentially get a 100 percent tax break on the expenses incurred from that research (about 70 percent of which are normally wages). If they instead outsource that research to a CRO, they may claim only 65 percent of eligible expenses. The CRO gets no tax break, so that 35 percent difference simply disappears. If a group of congressmen get their way, that situation might soon change.

  • Genome Sequencing - The Key To The Cancer Moonshot?
    Genome Sequencing - The Key To The Cancer Moonshot?

    Though the announcement may seem recent, it was actually in October of last year when Vice President Biden boldly announced the “moonshot to cure cancer,” a personal passion fueled by his son’s death from the disease. Half a year later, this tall-order still has the industry – and world’s – attention, remaining the cause of consistent speculation and debate.

  • France Tragedy Update: Bial & Biotrial At Fault; EMA Reviews Guidelines
    France Tragedy Update: Bial & Biotrial At Fault; EMA Reviews Guidelines

    After the clinical tragedy in France in January, the French Health Ministry has found blame with the two companies involved in the trial, noting Bial and Biotrial were at fault on several counts. The EU has guidelines in place to ensure that does not happen again.

  • After Government Debacle, Is It Any Easier To Perform Clinical Trials In India?
    After Government Debacle, Is It Any Easier To Perform Clinical Trials In India?

    In May 2014, I interviewed Mithra Bindhu of India-based Asiatic Clinical Research to get an update on performing clinical trials in that country. The DCGI (Drug Controller General of India) had recently attempted to overhaul the entire system, which took a long time, complicated the process of conducting trials in India, and caused some sponsors to question the value of doing business there. Has the situation changed?

More Featured Articles

WHITE PAPERS AND CASE STUDIES

  • Bioanalysis Of Biosimilars

    Assessment of biosimilarity during non-clinical and clinical trials requires specific bioanalytical procedures. The concentration of the biosimilars and their reference compounds is established using pharmacokinetic (PK) methods. By BARRY van der STRATE, PhD, Associate Director of Science, Large Molecules, PRA Health Sciences; CHAD BRISCOE, PhD Executive Director of Science & Innovation Bioanalytical Services, PRA Health Sciences

  • ICON Clinical Development Overview

    ICON is one of the world’s largest providers of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialise in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies.

  • Physical & Chemical Analysis Datasheet We provide a full suite of cGMP analytical testing services to support the quality control and research and development needs of the pharmaceutical industry.
  • Early-Phase Metabolic Development Datasheet ICON’s consultancy services advise on clinical pharmacology study designs based on preclinical data – including potential use of surrogate markers and pharmacodynamic models, validation of those markers and models, clear objective setting and flexible protocol design.
  • Clinical Pharmacology Datasheet

    The clinical pharmacology team at ICON Development Solutions (ICON) has extensive experience in the design, study conduct and interpretation of clinical pharmacology studies across all major therapeutic areas.

  • Early Phase Development Datasheet

    ICON Development Solutions specializes in the strategy and delivery of early phase clinical development for informed, timely decision making. With expertise in early phase clinical research, bioanalytical, PK/PD modelling & simulation and the full range of supporting services, we incorporate scientific excellence and product development strategy in all that we do.

More White Papers & Case Studies

SERVICES AND PRODUCTS

Bioanalytical Laboratories Bioanalytical Laboratories

With over 1,500 assays developed in support of over 2,500 studies and with management experience averaging 21 years, ICON Development Solutions has the bioanalytical expertise and track record required to deliver rapid, dependable results. 

Dry Blood Spot Analysis Dry Blood Spot Analysis
ICON offers dry blood spot analysis as a convenient and practical solution when sampling from populations where sample volume is at a premium or where analyte stability is an issue.
Clinical Pharmacology Clinical Pharmacology

The clinical pharmacology team at ICON Development Solutions (ICON) has extensive experience in the design, study conduct and interpretation of clinical pharmacology studies across all major therapeutic areas.

Clinical Development Laboratory Services Clinical Development Laboratory Services

ICON provides a full range of laboratory services that are dedicated exclusively to clinical development.

Clinical Pathology Clinical Pathology
ICON’s clinical pathology laboratory is an integral part of our pharmacology services. Co-located in our bioanalytical laboratory in Manchester - local to our hospital-based Clinical Pharmacology Unit - this laboratory provides real-time support for ICON’s Phase I studies, as well as external studies which are being conducted by leading CRO’s in the region.
Data Anaylsis Data Anaylsis
ICON is able to customise its database services based on clients' needs and preferred processes in all phases of clinical trials and pre-clinical studies.
More Services & Products

NEWS

More News

ABOUT